Quick Search 
Journals Home
Drugs of Today
Issues
Drugs of Today
Policies & Guidelines
Subscribe
Permissions
My
Profile
Contact
Us
Shopping
Cart
Purchase
History
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2020, 56(7): 431
ISSN 1699-3993
Copyright 2020 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2020.56.7.3151521		 
 
Diroximel fumarate to treat multiple sclerosis
Wang, Y., Bhargava, P.		 
 
On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl fumarate (DMF), was approved for the same indication on March 27, 2013. Prior to its approval, DRF did not undergo rigorous testing to determine its efficacy, as its active metabolite, monomethyl fumarate, is the same as that of DMF (bioequivalency). The efficacy, safety and tolerability of DMF have previously been demonstrated in a number of clinical trials and real-world studies. For DRF, one phase III study has been completed, and another is in progress to determine its safety, tolerability and efficacy. In this paper, we review the pharmacology, pharmacokinetics, metabolism, clinical studies and drug safety of DRF.


Full Text: PDF 		 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy